

# Cynthia Demicheli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12011334/publications.pdf>

Version: 2024-02-01

45  
papers

1,850  
citations

257357

24  
h-index

254106

43  
g-index

45  
all docs

45  
docs citations

45  
times ranked

2029  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pentavalent Antimonials: New Perspectives for Old Drugs. <i>Molecules</i> , 2009, 14, 2317-2336.	1.7	328
2	Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. <i>BioMetals</i> , 2003, 16, 441-446.	1.8	122
3	Glutathione-Induced Conversion of Pentavalent Antimony to Trivalent Antimony in Meglumine Antimoniate. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 913-916.	1.4	121
4	Oral Delivery of Meglumine Antimoniate- $\beta$ -Cyclodextrin Complex for Treatment of Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 100-103.	1.4	80
5	New delivery strategies for the old pentavalent antimonial drugs. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 1343-1358.	2.4	69
6	Reduced Tissue Parasitic Load and Infectivity to Sand Flies in Dogs Naturally Infected by Leishmania ( <i>L. infantum</i> ) Treated with Meglumine Antimoniate. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2564-2572.	1.4	67
7	Novel Triphenylantimony(V) and Triphenylbismuth(V) Complexes with Benzoic Acid Derivatives: Structural Characterization, in Vitro Antileishmanial and Antibacterial Activities and Cytotoxicity against Macrophages. <i>Molecules</i> , 2014, 19, 6009-6030.	1.7	66
8	Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines. <i>European Journal of Medicinal Chemistry</i> , 2016, 109, 254-267.	2.6	62
9	Lipossomas: propriedades físico-químicas e farmacológicas, aplicações na quimioterapia à base de antimônio. <i>Química Nova</i> , 2005, 28, 511-518.	0.3	58
10	New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 656-665.	1.5	54
11	Antimony(V) complex formation with adenine nucleosides in aqueous solution. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2002, 1570, 192-198.	1.1	51
12	Antimony(V) and Bismuth(V) Complexes of Lapachol: Synthesis, Crystal Structure and Cytotoxic Activity. <i>Molecules</i> , 2011, 16, 10314-10323.	1.7	51
13	Hepatotoxicity of Pentavalent Antimonial Drug: Possible Role of Residual Sb(III) and Protective Effect of Ascorbic Acid. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 481-488.	1.4	50
14	Efficacy of Combined Therapy with Liposome-Encapsulated Meglumine Antimoniate and Allopurinol in Treatment of Canine Visceral Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2858-2867.	1.4	47
15	Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. <i>International Journal of Pharmaceutics</i> , 2006, 315, 140-147.	2.6	45
16	Interaction of trivalent antimony with a CCHC zinc finger domain: potential relevance to the mechanism of action of antimonial drugs. <i>Chemical Communications</i> , 2008, , 4828.	2.2	42
17	Enhanced oral delivery of antimony from meglumine antimoniate/ $\beta$ -cyclodextrin nanoassemblies. <i>International Journal of Pharmaceutics</i> , 2008, 347, 102-108.	2.6	39
18	Mode of action of $\beta$ -cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate. <i>International Journal of Pharmaceutics</i> , 2006, 325, 39-47.	2.6	37

#	ARTICLE	IF	CITATIONS
19	Cytotoxicity and <i>In Vitro</i> Antileishmanial Activity of Antimony (V), Bismuth (V), and Tin (IV) Complexes of Lapachol. <i>Bioinorganic Chemistry and Applications</i> , 2013, 2013, 1-7.	1.8	35
20	Improved Antileishmanial Activity of Dppz through Complexation with Antimony(III) and Bismuth(III): Investigation of the Role of the Metal. <i>Molecules</i> , 2012, 17, 12622-12635.	1.7	34
21	Pentavalent organoantimonial derivatives: two simple and efficient synthetic methods for meglumine antimonate. <i>Applied Organometallic Chemistry</i> , 2003, 17, 226-231.	1.7	31
22	Amphiphilic Antimony(V) Complexes for Oral Treatment of Visceral Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4229-4236.	1.4	30
23	Role of residual Sb(III) in meglumine antimonate cytotoxicity and MRP1-mediated resistance. <i>Chemico-Biological Interactions</i> , 2006, 160, 217-224.	1.7	26
24	Greater binding affinity of trivalent antimony to a CCCH zinc finger domain compared to a CCHC domain of kinetoplastid proteins. <i>Metallomics</i> , 2012, 4, 433.	1.0	26
25	Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite. <i>Journal of Biological Inorganic Chemistry</i> , 2015, 20, 771-779.	1.1	24
26	Physico-chemical characterization of meglumine antimonate. <i>BioMetals</i> , 1999, 12, 63-66.	1.8	23
27	Enhanced schistosomicidal efficacy of tartar emetic encapsulated in pegylated liposomes. <i>International Journal of Pharmaceutics</i> , 2003, 255, 227-230.	2.6	23
28	Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 1551-1560.	2.4	23
29	Characterization of reactions of antimonate and meglumine antimonate with a guanine ribonucleoside at different pH. <i>BioMetals</i> , 2006, 19, 573-581.	1.8	22
30	Chemistry of antimony-based drugs in biological systems and studies of their mechanism of action. <i>Reviews in Inorganic Chemistry</i> , 2013, 33, 1-12.	1.8	19
31	Synthesis and characterization of Sb(V)-adenosine and Sb(V)-guanosine complexes in aqueous solution. <i>Inorganica Chimica Acta</i> , 2006, 359, 159-167.	1.2	18
32	Complexes of different nitrogen donor heterocyclic ligands with SbCl <sub>3</sub> and PhSbCl <sub>2</sub> as potential antileishmanial agents against Sb(III)-sensitive and -resistant parasites. <i>Journal of Inorganic Biochemistry</i> , 2014, 132, 30-36.	1.5	17
33	Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis. <i>International Journal of Nanomedicine</i> , 2016, 11, 2305.	3.3	17
34	Prolonged absorption of antimony(V) by the oral route from non-inclusion meglumine antimonate- $\beta$ -cyclodextrin conjugates. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 109-119.	1.1	15
35	Combination oral therapy against <i>Leishmania amazonensis</i> infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine. <i>Parasitology Research</i> , 2019, 118, 3077-3084.	0.6	13
36	Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs. <i>Molecules</i> , 2014, 19, 5478-5489.	1.7	12

#	ARTICLE	IF	CITATIONS
37	Nanoparticle phosphate-based composites as vehicles for antimony delivery to macrophages: possible use in leishmaniasis. <i>Journal of Materials Chemistry B</i> , 2015, 3, 9250-9259.	2.9	10
38	Kinetics of antimony(V) reduction by L-cysteine: pharmacological implications and application to the determination of antimony in pentavalent antimonial drugs. <i>Journal of the Brazilian Chemical Society</i> , 2006, 17, 1642-1650.	0.6	7
39	Influence of the nucleobase on the physicochemical characteristics and biological activities of SbV-ribonucleoside complexes. <i>Journal of the Brazilian Chemical Society</i> , 2010, 21, 1258-1265.	0.6	7
40	Efficacy of Meglumine Antimoniate in a Low Polymerization State Orally Administered in a Murine Model of Visceral Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	7
41	Reactive oxygen species generating photosynthesized ferromagnetic iron oxide nanorods as promising antileishmanial agent. <i>Nanomedicine</i> , 2020, 15, 755-771.	1.7	7
42	Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with <i>Leishmania infantum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
43	Use of liposomal nanoformulations in antileishmania therapy: challenges and perspectives. <i>Journal of Liposome Research</i> , 2021, 31, 169-176.	1.5	6
44	Nanostructures for Improved Antimonial Therapy of Leishmaniasis. , 2017, , 419-437.		2
45	Redox-Active Metal Complexes in Trypanosomatids. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2016, , 669-681.	0.4	0